Adjuvant topical chemotherapy versus immunotherapy in primary superficial transitional cell carcinoma of the bladder.
In a prospective randomised controlled study, the efficacy of ethoglucid was compared with that of keyhole-limpet haemocyanin (KLH) in preventing recurrent tumours following transurethral resection of primary superficial transitional cell carcinoma of the bladder. Patients treated with ethoglucid (n = 39) received 0.565 g (1% solution) ethoglucid weekly for 6 weeks and then monthly for 1 year. Patients treated with KLH (n = 38) were immunised subcutaneously with 1 mg KLH; bladder instillations of 30 mg were then given weekly for 6 weeks and thereafter monthly for 1 year. The recurrence rates, disease-free intervals and tumour progression rates were evaluated. The end-point of the study was either progression in stage or grade or more than 1 recurrence during the observation period. The minimum length of follow-up was 1 year. The recurrence rates, mean disease-free intervals and progression rates in the 2 groups showed no statistically significant differences.
Flamm
J
J
Department of Urology, Wilhelminen Hospital, Vienna, Austria.
Bucher
A
A
D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005009:Ethoglucid / Q000627:therapeutic use*; D005260:Female; D006433:Hemocyanins / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D011446:Prospective Studies; D012307:Risk Factors; D001749:Urinary Bladder Neoplasms / Q000601:surgery / Q000628:therapy*
D005009:Ethoglucid; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin